Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17–48.

Article  PubMed  Google Scholar 

Lowrance WT, Murad MH, Oh WK, Jarrard DF, Resnick MJ, Cookson MS. Castration-resistant prostate cancer: AUA Guideline Amendment 2018. J Urol. 2018;200:1264–72.

Article  PubMed  Google Scholar 

Schaeffer E, Srinivas S, Antonarakis ES, Armstrong AJ, Bekelman JE, Cheng H, et al. NCCN guidelines insights: prostate cancer, Version 1.2021. J Natl Compr Cancer Netw. 2021;19:134–43.

Article  CAS  Google Scholar 

Crocetto F, Russo G, Di Zazzo E, Pisapia P, Mirto BF, Palmieri A, et al. Liquid biopsy in prostate cancer management-current challenges and future perspectives. Cancers. 2022;14:3272.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Trujillo B, Wu A, Wetterskog D, Attard G. Blood-based liquid biopsies for prostate cancer: clinical opportunities and challenges. Br J Cancer. 2022;127:1394–402.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tulpule V, Morrison GJ, Falcone M, Quinn DI, Goldkorn A. Integration of liquid biopsies in clinical management of metastatic prostate cancer. Curr Oncol Rep. 2022;24:1287–98.

Article  CAS  PubMed  Google Scholar 

de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008;14:6302–9.

Article  PubMed  Google Scholar 

Scher HI, Jia X, de Bono JS, Fleisher M, Pienta KJ, Raghavan D, et al. Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol. 2009;10:233–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Goldkorn A, Ely B, Quinn DI, Tangen CM, Fink LM, Xu T, et al. Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol. 2014;32:1136–42.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Heller G, McCormack R, Kheoh T, Molina A, Smith MR, Dreicer R, et al. Circulating tumor cell number as a response measure of prolonged survival for metastatic castration-resistant prostate cancer: a comparison with prostate-specific antigen across five randomized Phase III clinical trials. J Clin Oncol. 2018;36:572–80.

Article  CAS  PubMed  Google Scholar 

Wang C, Zhang Z, Chong W, Luo R, Myers RE, Gu J, et al. Improved prognostic stratification using circulating tumor cell clusters in patients with metastatic castration-resistant prostate cancer. Cancers. 2021;13:268.

Article  CAS  PubMed  PubMed Central  Google Scholar 

van der Toom EE, Axelrod HD, de la Rosette JJ, de Reijke TM, Pienta KJ, Valkenburg KC. Prostate-specific markers to identify rare prostate cancer cells in liquid biopsies. Nat Rev Urol. 2019;16:7–22.

Article  PubMed  PubMed Central  Google Scholar 

Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N. Engl J Med. 2014;371:1028–38.

Article  PubMed  PubMed Central  Google Scholar 

Antonarakis ES, Lu C, Luber B, Wang H, Chen Y, Zhu Y, et al. Clinical significance of androgen receptor splice variant-7 mRNA detection in circulating tumor cells of men with metastatic castration-resistant prostate cancer treated with First- and Second-Line Abiraterone and Enzalutamide. J Clin Oncol. 2017;35:2149–56.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nagaya N, Nagata M, Lu Y, Kanayama M, Hou Q, Hotta ZU, et al. Prostate-specific membrane antigen in circulating tumor cells is a new poor prognostic marker for castration-resistant prostate cancer. PLoS One. 2020;15:e0226219.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Francolini G, Loi M, Ciccone LP, Detti B, Di Cataldo V, Pinzani P, et al. Prospective assessment of AR splice variant and multi-biomarker expression on circulating tumor cells of mCRPC patients undergoing androgen receptor targeted agents: interim analysis of PRIMERA trial (NCT04188275). Med Oncol. 2022;39:119.

Article  CAS  PubMed  Google Scholar 

Nuhn P, De Bono JS, Fizazi K, Freedland SJ, Grilli M, Kantoff PW, et al. Update on systemic prostate cancer therapies: management of metastatic castration-resistant prostate cancer in the era of precision oncology. Eur Urol. 2019;75:88–99.

Article  PubMed  Google Scholar 

Xu J, Kalos M, Stolk JA, Zasloff EJ, Zhang X, Houghton RL, et al. Identification and characterization of prostein, a novel prostate-specific protein. Cancer Res. 2001;61:1563–8.

CAS  PubMed  Google Scholar 

Sheridan T, Herawi M, Epstein JI, Illei PB. The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate. Am J Surg Pathol. 2007;31:1351–5.

Article  PubMed  Google Scholar 

Ried K, Tamanna T, Matthews S, Eng P, Sali A. New screening test improves detection of prostate cancer using circulating tumor cells and prostate-specific markers. Front Oncol. 2020;10:582.

Article  PubMed  PubMed Central  Google Scholar 

Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working Group 3. J Clin Oncol. 2016;34:1402–18.

Article  PubMed  PubMed Central  Google Scholar 

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.

Article  CAS  PubMed  Google Scholar 

Casanova-Salas I, Athie A, Boutros PC, Del Re M, Miyamoto DT, Pienta KJ, et al. Quantitative and qualitative analysis of blood-based liquid biopsies to inform clinical decision-making in prostate cancer. Eur Urol. 2021;79:762–71.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Scher HI, Graf RP, Schreiber NA, Jayaram A, Winquist E, McLaughlin B, et al. Assessment of the validity of nuclear-localized androgen receptor splice variant 7 in circulating tumor cells as a predictive biomarker for castration-resistant prostate cancer. JAMA Oncol. 2018;4:1179–86.

Article  PubMed  PubMed Central  Google Scholar 

De Laere B, Oeyen S, Mayrhofer M, Whitington T, van Dam PJ, Van Oyen P, et al. TP53 outperforms other androgen receptor biomarkers to predict Abiraterone or Enzalutamide outcome in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2019;25:1766–73.

Article  PubMed  Google Scholar 

Tommasi S, Pilato B, Carella C, Lasorella A, Danza K, Vallini I, et al. Standardization of CTC AR-V7 PCR assay and evaluation of its role in castration resistant prostate cancer progression. Prostate. 2019;79:54–61.

Article  CAS  PubMed  Google Scholar 

Uhlen M, Fagerberg L, Hallstrom BM, Lindskog C, Oksvold P, Mardinoglu A, et al. Proteomics. Tissue-based map of the human proteome. Science. 2015;347:1260419.

Article  PubMed  Google Scholar 

Yin M, Dhir R, Parwani AV. Diagnostic utility of p501s (prostein) in comparison to prostate specific antigen (PSA) for the detection of metastatic prostatic adenocarcinoma. Diagn Pathol. 2007;2:41.

Article  PubMed  PubMed Central  Google Scholar 

Chuang AY, DeMarzo AM, Veltri RW, Sharma RB, Bieberich CJ, Epstein JI. Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma. Am J Surg Pathol. 2007;31:1246–55.

Article  PubMed  Google Scholar 

Srinivasan M, Parwani AV. Diagnostic utility of p63/P501S double sequential immunohistochemical staining in differentiating urothelial carcinoma from prostate carcinoma. Diagn Pathol. 2011;6:67.

Article  PubMed  PubMed Central  Google Scholar 

Epstein JI, Egevad L, Humphrey PA, Montironi R, Members of the IIiDUPG. Best practices recommendations in the application of immunohistochemistry in the prostate: report from the International society of urologic pathology consensus conference. Am J Surg Pathol. 2014;38:e6–e19.

Article  PubMed  Google Scholar 

Mochizuki K, Kawai M, Odate T, Tahara I, Inoue T, Kasai K, et al. Diagnostic utility of prostein, Uroplakin II and SATB2 for diagnosing carcinoma of unknown primary origin: a systematic immunohistochemical profiling. Anticancer Res. 2018;38:4759–66.

Article  CAS  PubMed  Google Scholar 

Musiyenko A, Bitko V, Barik S. Ectopic expression of miR-126*, an intronic product of the vascular endothelial EGF-like 7 gene, regulates prostein translation and invasiveness of prostate cancer LNCaP cells. J Mol Med. 2008;86:313–22.

Article  CAS  PubMed  Google Scholar 

Kiessling A, Wehner R, Fussel S, Bachmann M, Wirth MP, Schmitz M. Tumor-associated antigens for specific immunotherapy of prostate cancer. Cancers. 2012;4:193–217.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pin E, Henjes F, Hong MG, Wiklund F, Magnusson P, Bjartell A, et al. Identification of a Novel autoimmune peptide epitope of prostein in prostate cancer. J Proteome Res. 2017;16:204–16.

Article  CAS  PubMed